Chk2 Monoclonal Antibody

In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutati

Introducing the CHK2 Monoclonal Antibody, a cutting-edge biotechnological product designed to revolutionize the field of cancer research and diagnostics. This highly specific and sensitive antibody is meticulously engineered to target and detect the CHK2 protein, a crucial regulator of cell cycle checkpoints and DNA damage response pathways.

The CHK2 Monoclonal Antibody boasts exceptional affinity and selectivity, enabling precise identification and quantification of CHK2 protein expression levels in various biological samples. Its superior performance ensures accurate and reliable results, facilitating comprehensive investigations into the role of CHK2 in cancer development, progression, and therapeutic response.

Crafted with utmost precision and rigorously validated, this antibody guarantees reproducibility and consistency across experiments, empowering researchers to confidently explore the intricate mechanisms underlying CHK2-mediated cellular processes. Its exceptional sensitivity allows for the detection of even low-abundance CHK2 protein, enabling the identification of subtle alterations in its expression that may have significant implications in cancer biology.

The CHK2 Monoclonal Antibody is compatible with a wide range of applications, including Western blotting, immunohistochemistry, immunofluorescence, and flow cytometry. Its versatility and adaptability make it an invaluable tool for both basic research and clinical investigations, facilitating the elucidation of CHK2-associated molecular pathways and the development of novel therapeutic strategies.

With its exceptional performance, reliability, and versatility, the CHK2 Monoclonal Antibody represents a breakthrough in cancer research and diagnostics. Empower your scientific endeavors with this state-of-the-art antibody and unlock new insights into the intricate world of CHK2 biology.